Reports Q3 revenue EUR 213.63M vs. EUR 57.83M last year. “With our achievements in the third quarter and year to date, Ascendis is making great progress toward achieving Vision 2030. The ongoing strong global launch of YORVIPATH is transforming our financial profile and, based on positive feedback from physicians and patients, we expect to continue to build on this momentum,” said Jan Mikkelsen, Ascendis Pharma’s (ASND) president and CEO. “With TransCon CNP now under FDA and EMA review, we are on the verge of bringing our third high-value medicine to patients, and we expect our engine for future innovation to drive sustainable growth for years to come.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- ASND Earnings this Week: How Will it Perform?
- Ascendis Pharma announces new pooled analysis on TransCon PTH
- Ascendis Pharma Launches Expanded SKYTROFA Dosing in U.S.
- RBC Capital remains buyer of Ascendis, says patient death unlikely drug related
- Ascendis Pharma weakness follows death reported in FAERS, says BofA